moleculin biotech, INC. (NASDAQ:MBRX) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
|
Results of Operations and Financial Condition. |
On November 21, 2016, Moleculin Biotech, Inc. issued a press
release announcing its financial results for the period ended
September 30, 2016 and recent operational highlights. A copy of
the press release is attached to this report as Exhibit 99.1 and
is incorporated by reference herein.
In accordance with General Instruction B.2. of Form 8-K, the
information in this Current Report on Form 8-K, including Exhibit
99.1, shall not be deemed to be filed for purpose of Section 18
of the Securities and Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liabilities of that
section, and shall not be deemed incorporated by reference into
any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| Exhibit No. | Description |
| 99.1 | Moleculin Biotech, Inc. press release dated November 21, 2016 |
About moleculin biotech, INC. (NASDAQ:MBRX)
Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates, many of which are based on license agreements. The Company’s lead drug candidate is liposomal Annamycin (Annamycin). The Company has two other drug development projects in progress, one involving a portfolio of small molecules, known as the WP1066 Portfolio, and the other is WP1122 Portfolio. WP1066 Portfolio is focused on the modulation of key regulatory transcription factors involved in the progression of cancer. WP1122 Portfolio is a suite of molecules targeting the metabolic processes involved in cancer in general and glioblastoma (a form of brain tumor). Anthracyclines are anticancer drugs developed and are used to treat a range of cancers, including leukemia, lymphomas, and breast, stomach, uterine, ovarian, bladder and lung cancers. moleculin biotech, INC. (NASDAQ:MBRX) Recent Trading Information
moleculin biotech, INC. (NASDAQ:MBRX) closed its last trading session up +0.03 at 2.98 with 35,585 shares trading hands.
